Author name: Prarthana Patnaik

Thematic Highlight Prof. Basheer wrote another post on the Novartis AG v. Union of India decision in continuation to his earlier post on a Chinese blockbuster inspired by the Novartis decision. In the first half of his post, he focuses on the Court’s strict construction of the term ‘efficacy’ under Section 3(d) and how Novartis was unable to prove the same in its anti-cancer drug Glivec. He then recounts several flaws in the Court’s reasoning and the decision-making process. He then analyses […]

It’s been an interesting week at SpicyIP! Thematic Highlight The second guest post by Prof. (Dr.) N.S. Gopalakrishnan forms the thematic highlight of this week. In continuation to his first post, Prof. Gopalakrishnan states that there has been no report of an individual registering a new variety under the Protection of Plant Varieties and Farmers’ Right Act, 2001 till date. He then proceeds to describe how certain provisions and rules under the Act create confusion with regard to notification of

This week, we had a post by Prashant, which forms the latest update on the ongoing debate about the Bedaquiline issue. (Previous SpicyIP posts on this issue by Prashant and Balaji can be accessed here.). In his latest post, Prashant responded to Anand Grover’s take on his views and disagreed with him on multiple aspects. He countered Grover’s argument on increasing access to bedaquiline by questioning the decision of Indian authorities to approve this drug when Phase III trials are